Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.

Laille, Eric; Shi, Tao; Garcia-Manero, Guillermo; Cogle, Christopher R; Gore, Steven D; Hetzer, Joel; Kumar, Keshava; Skikne, Barry; MacBeth, Kyle J

Laille, Eric; Shi, Tao; Garcia-Manero, Guillermo; Cogle, Christopher R; Gore, Steven D; Hetzer, Joel; Kumar, Keshava; Skikne, Barry; MacBeth, Kyle J.

Affiliation

Laille E; Celgene Corporation, Summit, New Jersey, United States of America.
Shi T; Celgene Corporation, Summit, New Jersey, United States of America.
Garcia-Manero G; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, United States of America.
Cogle CR; Division of Hematology/Oncology, University of Florida, Gainesville, Florida, United States of America.
Gore SD; Yale Cancer Center, New Haven, Connecticut, United States of America.
Hetzer J; Celgene Corporation, Summit, New Jersey, United States of America.
Kumar K; Celgene Corporation, Summit, New Jersey, United States of America.
Skikne B; Celgene Corporation, Summit, New Jersey, United States of America.
MacBeth KJ; Celgene Corporation, Summit, New Jersey, United States of America.

PLoS One ; 10(8): e0135520, 2015.

Article in En | MEDLINE | ID: mdl-26296092

Subject(s)

Antimetabolites, Antineoplastic/pharmacokinetics; Azacitidine/pharmacokinetics; Leukemia, Myeloid, Acute/drug therapy; Leukemia, Myelomonocytic, Chronic/drug therapy; Myelodysplastic Syndromes/drug therapy; Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic/blood; Antimetabolites, Antineoplastic/therapeutic use; Area Under Curve; Azacitidine/blood; Azacitidine/therapeutic use; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Epigenesis, Genetic; Half-Life; Humans; Leukemia, Myeloid, Acute/genetics; Leukemia, Myeloid, Acute/mortality; Leukemia, Myeloid, Acute/pathology; Leukemia, Myelomonocytic, Chronic/genetics; Leukemia, Myelomonocytic, Chronic/mortality; Leukemia, Myelomonocytic, Chronic/pathology; Male; Middle Aged; Myelodysplastic Syndromes/genetics; Myelodysplastic Syndromes/mortality; Myelodysplastic Syndromes/pathology; Survival Analysis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Azacitidine / Myelodysplastic Syndromes / Leukemia, Myelomonocytic, Chronic / Leukemia, Myeloid, Acute / Antimetabolites, Antineoplastic Type of study: Prognostic_studies Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2015 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google